# A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes

> **NCT02132637** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 68 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Insulin Peglispro
- **DRUG:** Insulin Glargine

## Key facts

- **NCT ID:** NCT02132637
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2019-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02132637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02132637, "A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02132637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*